Vident Investment Advisory LLC purchased a new position in NewLink Genetics Corp (NASDAQ:NLNK) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 150,540 shares of the biotechnology company’s stock, valued at approximately $1,221,000. Vident Investment Advisory LLC owned approximately 0.41% of NewLink Genetics at the end of the most recent reporting period.
Other institutional investors have also recently made changes to their positions in the company. Perceptive Advisors LLC bought a new position in NewLink Genetics in the 3rd quarter worth about $4,581,000. Virtus Fund Advisers LLC bought a new position in NewLink Genetics in the 4th quarter worth about $336,000. Virtu Financial LLC bought a new position in NewLink Genetics in the 4th quarter worth about $798,000. Northern Trust Corp boosted its stake in NewLink Genetics by 4.0% in the 2nd quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock worth $2,195,000 after purchasing an additional 11,532 shares in the last quarter. Finally, Neuberger Berman Group LLC bought a new position in NewLink Genetics in the 3rd quarter worth about $305,000. Institutional investors own 65.05% of the company’s stock.
Several equities analysts have issued reports on NLNK shares. Cantor Fitzgerald set a $26.00 target price on shares of NewLink Genetics and gave the company a “buy” rating in a research note on Friday, March 2nd. Stifel Nicolaus restated a “buy” rating and set a $21.00 target price (down previously from $25.00) on shares of NewLink Genetics in a research note on Friday, March 2nd. Bank of America lowered their target price on shares of NewLink Genetics from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, March 2nd. Zacks Investment Research upgraded shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $9.00 target price on the stock in a research note on Wednesday, January 3rd. Finally, BidaskClub upgraded shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $21.57.
Shares of NewLink Genetics stock opened at $7.24 on Thursday. NewLink Genetics Corp has a fifty-two week low of $5.90 and a fifty-two week high of $25.17.
NewLink Genetics (NASDAQ:NLNK) last released its earnings results on Thursday, March 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.32. The company had revenue of $10.10 million during the quarter, compared to analyst estimates of $2.72 million. NewLink Genetics had a negative net margin of 250.60% and a negative return on equity of 60.60%. research analysts anticipate that NewLink Genetics Corp will post -2.35 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/03/22/vident-investment-advisory-llc-buys-shares-of-150540-newlink-genetics-corp-nlnk.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.